(Press-News.org) Ewing sarcoma tumors disappeared and did not return in more than 70 percent of mice treated with combination therapy that included drugs from a family of experimental agents developed to fight breast cancer, reported St. Jude Children's Research Hospital scientists. The study will appear in the November 6 edition of the scientific journal Cell Reports.
The treatment paired two chemotherapy drugs currently used to treat Ewing sarcoma (EWS) with experimental drugs called poly-ADP ribose polymerase (PARP) inhibitors that interfere with DNA repair. PARP inhibitors are currently in clinical trials for the treatment of certain breast and ovarian cancers as well as other solid tumors. EWS is a cancer of the bone and soft tissue that strikes primarily adolescents and young adults.
A clinical trial using the three-drug combination therapy detailed in this research is expected to open later this year for adolescents and young adults with EWS whose tumors have not disappeared with standard therapy or have returned after treatment. The trial is a collaboration of researchers at St. Jude and the Dana-Farber/Harvard Cancer Center in Boston. The therapy will pair the PARP inhibitor olaparib with the chemotherapy drugs irinotecan (IRN) and temozolomide (TMZ).
The study is one of two clinical trials St. Jude plans to open soon combining IRN and TMZ with PARP inhibitors for the treatment for EWS. The tumor is diagnosed in about 250 U.S. residents each year, making it the second most common bone tumor in children and adolescents.
Long-term survival for EWS patients whose disease has not spread remains stalled at about 75 to 80 percent, and the outcome for patients with metastatic disease is dismal. "During the past 20 years there has been no significant improvement in the cure rate for Ewing sarcoma, and survival is just 15 to 20 percent for patients whose disease has spread or comes back after treatment," said co-corresponding author Michael Dyer, Ph.D., a Howard Hughes Medical Institute (HHMI) investigator and a member of the St. Jude Department of Developmental Neurobiology. The other corresponding author is Anang Shelat, Ph.D., an assistant member of the St. Jude Department of Chemical Biology and Therapeutics.
This study builds on earlier research from other investigators who reported that EWS cells growing in the laboratory were sensitive to the PARP inhibitor olaparib. A clinical trial of olaparib for treatment of adults with EWS that had spread or returned opened a short time later.
The latest report includes the St. Jude discovery that EWS cells have a defect in DNA damage repair. DNA is the molecule contained in nearly every cell that carries the instructions needed to assemble and sustain life.
Working with EWS cells grown in the laboratory and mice, investigators showed the EWS defect could be exploited to help patients by combining DNA-damaging chemotherapy with a PARP inhibitor. PARP inhibitors work by interfering with activity of an important DNA-repair enzyme.
St. Jude researchers conducted a series of mouse experiments designed to mirror the human phase I, II and III studies that gauge the safety and effectiveness of experimental treatment in humans. The research showed that PARP inhibitors work synergistically with IRN and TMZ to kill EWS. The Phase III study included 274 mice with EWS treated in a double-blind, placebo controlled, randomized study. The study included 15 different treatment groups using different combinations and doses of IRN, TMZ and three PARP inhibitors currently in development for pediatric cancer treatment.
EWS disappeared and had not returned in more than four months in 71 percent of mice treated with IRN, TMZ and the PARP inhibitor olaparib. The results were even better when IRN and TMZ were combined with the PARP inhibitor talazoparib. The combination led to a durable, complete remission in 88 percent of the 16 mice treated.
"Our preclinical results suggest Ewing sarcoma is particularly sensitive to this combination therapy, a possible indication that the tumor's DNA repair defect provides us with a much needed advantage to knock out tumor cells," Shelat said. "There is some evidence that this type of defect is present in other pediatric tumors, and we are actively investigating drug sensitivity in those cancers."
Researchers used the low-dose, protracted IRN treatment schedule pioneered at St. Jude to reduce IRN toxicity. Adult cancer patients receive fewer, but higher doses of IRN. The adult treatment regimen led to higher toxicity in mice. "The only way to move forward was using the irinotecan approach proven in earlier St. Jude solid tumor clinical research," Dyer said.
One of the planned St. Jude-led clinical trials will combine talazoparib and IRN for the treatment of patients age 1 and older. The other will involve triple drug therapy for treatment of patients age 16 and older.
INFORMATION:
The study's first author is Elizabeth Stewart, M.D., a research associate in the St. Jude Department of Oncology. The other authors are Ross Goshorn, Cori Bradley, Lyra Griffiths, Nathaniel Twarog, William Caufield, Burgess Freeman III, Armita Bahrami, Alberto Pappo, Jianrong Wu, Asa Karlstrom, Chris Calabrese, Brittney Gordon, Lyudmila Tsurkan, M. Jason Hatfield, Philip Potter, Scott Snyder, Suresh Thiagarajan, Abbas Shirinifard and Andras Sablauer, all of St. Jude; and Claudia Benavente, Gregory Miller and Amos Loh, all formerly of St. Jude.
The research was funded in part by grants (CA21765, CA168875) from the National Cancer Institute at the National Institutes of Health (NIH); grants (EY014867, EY018599) from the NIH; Alex's Lemonade Stand Foundation for Childhood Cancer, HHMI, the Tully Family Foundation and ALSAC.
ANN ARBOR, Mich. — Nearly two-thirds of patients treated for colorectal cancer reported some measure of financial burden due to their treatment, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.
The burden was greatest among patients who received chemotherapy and among younger patients who worked in low-paying jobs.
The study surveyed 956 patients who had been treated for stage 3 colorectal cancer. Among this group, chemotherapy is known to increase survival by up to 20 percent and is routinely recommended following ...
The strong southwesterly wind shear that has been battering Tropical Storm Ana has abated and has given the storm a chance to re-organize. Ana appeared more rounded on imagery from NASA's Terra satellite as thunderstorms again circled the low-level center.
NASA's Terra satellite passed over Ana on Oct. 22 at 22:10 UTC (6:10 p.m. EDT). The MODIS instrument aboard Terra captured a visible image of the storm that showed clouds and showers were no longer being blown northeast of the center from southwesterly wind shear, as they had in the last couple of days. The wind shear ...
Avoiding power struggles in the grocery store with children begging for sweets, chips and other junk foods – and parents often giving in – could be helped by placing the healthier options at the eye level of children and moving the unhealthy ones out of the way.
A new study by researchers at the Johns Hopkins Bloomberg School of Public Health found that this dynamic is particularly frustrating for caregivers on limited budgets who are trying to save money and make healthy meals.
The study, part of a project designed to encourage healthy food purchasing ...
A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause of maternal and infant death worldwide, a discovery that could lead to the development of new therapeutic treatments.
Nihar Nayak, D.V.M., Ph.D., is the principal investigator of the study, "Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications," published Oct. 20 in the online version of The Journal of Clinical Investigation. ...
PROVIDENCE, R.I. – John Boekamp, Ph.D., clinical director of the Pediatric Partial Hospital Program (PPHP) at Bradley Hospital recently led a study that found sleep difficulties - particularly problems with falling asleep - were very common among toddlers and preschool-aged children who were receiving clinical treatment for a wide range of psychiatric disorders. The study, titled "Sleep Onset and Night Waking Insomnias in Preschoolers with Psychiatric Disorders," is now published online in the journal Child Psychiatry & Human Development.
"The most common sleep ...
Having later sunsets may lead to an increase in children's physical activity, according to research by the London School of Hygiene & Tropical Medicine and the University of Bristol.
Over 23,000 children aged 5-16 years were studied in nine countries (England, Australia, USA, Norway, Denmark, Estonia, Switzerland, Brazil and Madeira, Portugal). The researchers examined associations between the time of sunset and physical activity levels, measured via waist-worn accelerometers (electronic devices that measure body movement).
Published in the open access journal International ...
CHAMPAIGN, Ill. — Here are three disaster scenarios for zoo or aquarium managers: One, a wildfire lunges towards your facility, threatening your staff and hundreds of zoo animals. Two, hurricane floodwaters pour into your basement, where thousands of exotic fish and marine mammals live in giant tanks. Three, local poultry farmers report avian influenza (bird flu) in their chickens, a primary source of protein for your big cats.
What do you do?
These are among the many potential disasters the managers of zoos and aquariums ponder in their emergency preparedness ...
A clinical drug trial conducted in five Sub-Sahara African countries shows that a shortened (four month) treatment for tuberculosis (TB) is well tolerated and may work well in subsets of TB patients, but overall could not be considered as an alternative to the current six month standard treatment. The results of the study were published in the New England Journal of Medicine.
TB remains a significant public health problem worldwide. There were an estimated 8.6 million people who developed TB and 1.3 million died from the disease in 2012. The study was designed to verify ...
New Rochelle, NY, October 23, 2014–Rapid lowering of body temperature following an acute myocardial infarction (MI) can be an effective therapeutic strategy to minimize damage to the heart muscle caused by the loss and restoration of blood flow to the heart. While hypothermia shows clinical promise, current methods to cool the heart are insufficient. Faster, more effective techniques are needed to realize the full cardioprotective potential of this emerging intervention, as described in an article in Therapeutic Hypothermia and Temperature Management, a peer-reviewed ...
CHAMPAIGN, Ill. — A new study finds that most U.S. adults fail to meet recommended daily levels of 10 key nutrients, and those with disabilities have even worse nutrition than average.
An estimated 10 to 25 percent of U.S. adults fit into one or more category of disability, from those who have difficulties with activities of daily living, such as dressing, bathing and eating, to those who cannot use their legs or struggle to accomplish routine tasks, such as money management or household chores.
To determine how these physical or mental difficulties can affect ...
